Immunotech Biopharm Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	54.46	46.96	52.16	58.45	353.34
Trading Asset Securities	100.11	10.54	124.81	21.01	-
Cash & Short-Term Investments	154.57	57.49	176.97	79.46	353.34
Cash Growth	168.84%	-67.51%	122.72%	-77.51%	-58.20%
Other Receivables	-	0.1	-	-	-
Receivables	-	0.1	-	-	-
Inventory	4.52	5.54	4.92	7.21	10.87
Other Current Assets	12.51	24.36	32	31.44	47.99
Total Current Assets	171.59	87.49	213.89	118.11	412.2
Property, Plant & Equipment	407	451.6	500.76	527.25	426.59
Long-Term Investments	-	-	46.36	140.18	163.18
Other Intangible Assets	17.9	19.55	41.88	42.49	14.25
Long-Term Deferred Charges	0.04	0.21	0.46	0.72	0.98
Other Long-Term Assets	6.4	5.18	42.92	50.69	80.5
Total Assets	602.94	564.04	846.28	879.44	1,098
Accounts Payable	35.23	33.61	46.76	37.39	32.15
Accrued Expenses	26.45	21	21.65	27.17	22.24
Short-Term Debt	0.21	-	-	-	-
Current Portion of Long-Term Debt	336.61	268.1	326.84	-	-
Current Portion of Leases	25.65	27.45	24.68	26.06	20.21
Current Income Taxes Payable	-	0.96	-	-	-
Current Unearned Revenue	1.37	1.78	1.85	4.36	5.19
Other Current Liabilities	65.34	77.31	108.5	113.49	100.31
Total Current Liabilities	490.85	430.21	530.28	208.47	180.1
Long-Term Debt	-	-	-	1	-
Long-Term Leases	77.79	89.02	105.66	122.75	90.85
Long-Term Unearned Revenue	51.5	61.27	39.46	40.84	3.56
Total Liabilities	620.14	580.5	675.39	373.07	274.51
Common Stock	4.31	3.58	3.58	3.58	3.58
Additional Paid-In Capital	-	1,402	1,402	1,402	1,402
Retained Earnings	-	-1,805	-1,618	-1,283	-965.22
Comprehensive Income & Other	-18.23	385.69	385.69	385.69	381.4
Total Common Equity	-13.93	-13.3	173.62	508.44	822.26
Minority Interest	-3.28	-3.16	-2.73	-2.07	0.92
Shareholders' Equity	-17.21	-16.45	170.89	506.37	823.18
Total Liabilities & Equity	602.94	564.04	846.28	879.44	1,098
Total Debt	440.26	384.56	457.17	149.81	111.05
Net Cash (Debt)	-285.7	-327.07	-280.2	-70.35	242.29
Net Cash Growth	-	-	-	-	-69.50%
Net Cash Per Share	-0.52	-0.64	-0.54	-0.14	0.47
Filing Date Shares Outstanding	617.5	514.58	514.58	514.58	514.58
Total Common Shares Outstanding	617.5	514.58	514.58	514.58	514.58
Working Capital	-319.26	-342.71	-316.38	-90.36	232.1
Book Value Per Share	-0.02	-0.03	0.34	0.99	1.60
Tangible Book Value	-31.83	-32.85	131.73	465.95	808.01
Tangible Book Value Per Share	-0.05	-0.06	0.26	0.91	1.57
Land	-	83.92	83.92	83.92	63.05
Machinery	-	153.36	149.53	86.1	76.5
Construction In Progress	-	113.42	107.65	208.53	151.85
Leasehold Improvements	-	121.83	121.83	56.69	56.25

Source: S&P Global Market Intelligence. Standard template. Financial Sources.